KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,141,990 | -53.8% | 815,707 | 0.0% | 0.08% | -56.0% |
| Q2 2023 | $2,471,592 | -51.5% | 815,707 | 0.0% | 0.19% | -43.2% |
| Q1 2023 | $5,098,169 | +2.5% | 815,707 | 0.0% | 0.34% | +8.0% |
| Q4 2022 | $4,975,813 | -49.0% | 815,707 | 0.0% | 0.31% | -33.1% |
| Q3 2022 | $9,748,000 | -5.2% | 815,707 | 0.0% | 0.46% | -8.3% |
| Q2 2022 | $10,286,000 | +46.3% | 815,707 | +30.7% | 0.51% | +36.7% |
| Q1 2022 | $7,029,000 | -28.3% | 624,236 | +12.9% | 0.37% | -20.0% |
| Q4 2021 | $9,801,000 | -14.6% | 553,128 | +11.0% | 0.46% | -21.9% |
| Q3 2021 | $11,476,000 | +64.3% | 498,528 | +66.2% | 0.59% | +91.6% |
| Q2 2021 | $6,984,000 | -25.3% | 300,000 | 0.0% | 0.31% | -19.7% |
| Q1 2021 | $9,348,000 | -21.7% | 300,000 | 0.0% | 0.39% | -24.6% |
| Q4 2020 | $11,934,000 | – | 300,000 | – | 0.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
| Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
| Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
| VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
| Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
| RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
| Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
| Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
| HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
| HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |